CREATING VALUE FROM UNIVERSITY DISCOVERIES
By accepting this document, and in consideration for it being made available to such recipient, each recipient agrees to keep strictly confidential the information contained in it and any information otherwise made available by Telcapital Plc ("the "Company"), whether orally or in writing, in the case of a corporate recipient, this presentation may only be disclosed, discussed, distributed or circulated, to any third party, in whole or in part, or published in whole or in part, or distributed, or acted upon or relied upon by persons who are not Relevant Persons. Any other person who receives this Presentation should not rely or act upon it. By accepting this presentation and not immediately returning it, the recipient is deemed to represent and warrant that: (i) they are a person who falls within the above description of persons; (ii) they have read and agree and will comply with the contents of this notice; and (iii) they will use the information in this document solely for evaluating your possible interest in acquiring securities of the Company.

The information contained in this confidential document (the "Presentation") has been prepared and distributed by the Company. It has not been fully verified and is subject to material updating, completion, revisions, verification and further amendment. This Presentation has not been approved by an authorised person in accordance with Section 21 of the Financial Services and Markets Act 2000, as amended ("FSMA"). This Presentation does not constitute, and the Company is not making, an offer of transferable securities to the public within the meaning of sections 858 and 1028 of FSMA and it is being delivered for information purposes only to a very limited number of persons and companies who are "qualified investors" within the meaning of section 86(7) of FSMA purchasing as principal or in circumstances under section 86(2) of FSMA, as well as persons who have professional experience in matters relating to investments and who fall within the category of persons set out in Article 19 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order") or are high net worth companies within the meaning set out in Article 49 of the Order or are a "professional client" or an "eligible counterparty" within the meaning of Article 4(11) of MiFID and (3) and (4), respectively, of Markets in Financial Instruments Directive (Directive 2004/39/EC) ("MiFID") as MiFID is implemented into national law of the relevant EEA state or are otherwise permitted to receive it (together, "Relevant Persons"). This Presentation is directed only at Relevant Persons and must not be acted on or relied upon by persons who are not Relevant Persons. Any other person who receives this Presentation should not rely or act upon it. By accepting this presentation and not immediately returning it, the recipient is deemed to represent and warrant that: (i) they are a person who falls within the above description of persons; (ii) they have read and agree and will comply with the contents of this notice; and (iii) they will use the information in this document solely for evaluating your possible interest in acquiring securities of the Company.

The securities mentioned herein have not been and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or under any U.S. state securities laws, and may not be offered or sold in the United States of America or its territories or possessions (the "United States") unless they are registered under the Securities Act or pursuant to an exempt transaction from or in a transaction not subject to the registration requirements of the Securities Act. Neither this Presentation nor any copy of it may be taken or transmitted in the United States, or distributed, directly or indirectly, in the United States, nor to "any person" as defined in the Securities Act, including US resident corporations or other entities organised under the laws of the United States or any state thereof or non-US branches or agencies of such corporations or entities. This Presentation is not being made available to persons in Australia, Canada, Japan, the Republic of Ireland, the Republic of South Africa or any other jurisdiction in which it may be unlawful to do so and it should not be delivered, distributed, directly or indirectly, within or within any such jurisdictions.

The information described in this Presentation may contain certain material information that is confidential, price-sensitive and which has not been publicly disclosed. By your receipt of this Presentation you recognise and accept that some or all of the information in this Presentation may be "inside information" as defined in Article 12 of the Market Abuse Regulation EU 576/2014 ("MAR") and the relevant provisions of FSMA, section 56 of the Criminal Justice Act 1993 ("CJA") and the Disclosure and Transparency Rules ("DTR") and constitutes a "market making" for the purpose of Article 11 of MAR. You recognise and accept that such information may be provided to you by the Company pursuant to Article 11 of MAR to the extent that you confirm, warrant and undertake that you will not: (i) deal in securities that are price-sensitive (as defined in the CJA) in relation to the inside information, encourage another person to deal in price-sensitive information except as permitted without incurring liability to the recipient of the inside information; (ii) disclose the inside information, sell or otherwise dispose of the information or opinions contained in this Presentation or for any of the opinions contained herein or for any errors, omissions or misstatements or for any loss, however arising, from the use of this Presentation.

Neither the use of this Presentation nor any part of its contents is to be taken as any form of contract, commitment or recommendation on the part of the Company or the directors of the Company to proceed with any transaction or accept any offer and the right is reserved to terminate any discussions or negotiations with any prospective investor. The Company reserves the right without any notice or liability to the recipient of this Presentation or its directors to: (i) change any of the procedures, timetable or requirements or terminate negotiations at any time prior to the signing of any binding agreement with investors; (ii) provide different information or access to information to different persons; (iii) agree variations to the property, rights and liabilities comprised in the Company; and (iv) negotiate at the same time with more than one person. In no circumstances will the Company be responsible for any costs, losses or expenses incurred in connection with any appraisal or investigation of the Company. This Presentation should not be considered a recommendation by the Company or any of its affiliated investment funds or any prospective acquisition of shares in the Company. Please be aware that the Company’s net asset value and financial results will fluctuate due to a wide variety of Company specific and macro-economic conditions.

No undertaking, representation, warranty or other assurance, express or implied, is made or given by or on behalf of the Company or any of its affiliates, any of its directors, officers or employees or any other person as to the accuracy or completeness of any of the information or opinions contained in this Presentation, and no responsibility or liability is accepted for any such information or opinions or for any errors or omissions.

Further, due to the Covid 19 pandemic, Company results, and net assets may be negatively impacted.
Providing technology transfer services for 250+ leading universities

Building portfolio companies with market-ready technology coupled with star power management

Multi-year track record of significant growth of net assets and returns on invested capital

“In addition to a growing portfolio of university IP investments, Tekcapital helps research institutions and businesses develop disruptive technologies and expand their portfolios of intellectual capital.” - Julian Mitchell
Our investment objective is significant growth of Net Assets, resulting from the commercialisation of compelling discoveries that can improve the quality of life for portfolio company costumers

- 2020 H1 Net Assets increased 16% to US$26.18m (30 Nov 2019: US$22.53m)

- 2020 H1 Total revenues US$2,859,647 (H1 2019: US$5,401,568)
  - Revenue from services US$557,684
  - Revenues from net increase in fair value of portfolio companies US$2,422,949

- Reduction of operating expenses by 4% to US$711,300 (H1 2019: US$740,947)
  - Service revenue cover appx. 58% of current cost base (H1 2019: 63%)

- 2020 H1 profit before tax: US $1.9m (H1 2019: US $4.4m)
We can review up to ~80%\(^1\) of the world’s university-developed IP from 4,500 research institutions. This helps mitigate adverse selection. Additionally, we are able to assess the market potential of any of these technologies with our Invention Evaluator reports & scientific advisory board.

\(^1\) Director’s estimate
OUR IP SERVICES

INVENTION DISCOVERY
Identify global university IP available for license

INVENTION EVALUATOR
Assess the market potential of new IP

TRAINING SERVICES
Programs for commercialising university IP

VORTECHS GROUP
Executive recruitment for university tech-transfer offices
PARTIAL CLIENT LIST

- Kraft
- CIPA
- IBM
- GW
- COPEC+UC
- ALDEYRA THERAPEUTICS™
- Edgewell™ PERSONAL CARE
- PREDICTIVE THERAPEUTICS
- Universidad del Desarrollo
- Universidad Adolfo Ibáñez
- SL INDUSTRIES
- Florida State University
- GE
- Johns Hopkins University
- Oregon Health & Science University
- PEPSICO
- Duke University Medical Center
- University of Minnesota
- Ohio
- Nationwide Children's
- United Therapeutics CORPORAION
- Innovate Arkansas
- Emory University
- AUTM
- Ford
CURRENT PORTFOLIO COMPANIES & PERCENTAGE SHARE OWNERSHIP

- **belluscura**: 16.2%
- **Salarius**: 97.2%*
- **lucyd**: 100%
- **guident**: 100%

*Salarius Ltd owns 87.1% of Microsalt Inc, its U.S. based subsidiary.
Premium Medical Devices at Value Prices

• Medical device company developing innovative oxygen therapy products

• Received FDA clearance for their X-PLO$_2$R™ portable oxygen concentrator on 8 March 2021.

• Completed development of X-PLO$_2$R portable oxygen concentrator and in Dec. 2020 submitted to U.S. FDA for 5-10 K clearance

• Feb 2020 Belluscura plc files new patent application for devices and systems for treating people suffering from acute respiratory distress caused by the Coronavirus.

• Capable & highly experienced management: Bob Rauker, CEO (previously Boston Scientific) Dr Raymond Bray, VP (previously St. Jude Medical).

• Belluscura raised US $2.7m in 2019 at 15p/share Post money valuation ~US $9m for the entire business.

• According to Grandview Research, the global medical O2 concentrator market was $1.75bn in 2018 (7.4% CAGR).¹

X-PLO$_2$R™ Portable Oxygen Concentrator

Anticipated Specifications

<table>
<thead>
<tr>
<th>Specification</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lightest</td>
<td>Only 1.25kg (2.8lbs)</td>
</tr>
<tr>
<td>Quiet</td>
<td>Only 39 dB</td>
</tr>
<tr>
<td>Reliable</td>
<td>Long battery duration</td>
</tr>
<tr>
<td>Modular</td>
<td>The first expandable POC with consumer replaceable filter cartridges</td>
</tr>
<tr>
<td>Strong IP</td>
<td>18 patents and pending applications</td>
</tr>
</tbody>
</table>

Tekcapital owns ~16.2% of Belluscura plc.

¹ https://www.grandviewresearch.com/industry-analysis/medical-oxygen-concentrators-market
Lucyd: the clear choice for tech eyewear

- Goal: Develop a successful global eShop providing prescription eyewear with advanced Bluetooth® technology.

- Sept. 2020. Lucyd receives notice of allowance on new IOT smart glass patent plus 12 design patents covering its smart glasses.

- Innovative Eyewear Inc, Lucyd’s subsidiary & licensee launched equity crowdfund in the U.S. As of 15 Feb. 2021, $705K has been raised from 2209 investors at a $3.75m pre-money valuation.

- Sept. 2020. Innovative Eyewear appointed Calvin Peters as eCommerce Growth, Content and Social Media Manager. Mr. Peters was formerly Sr. Manager of PR, Social Media and Influencer Marketing at the Walgreens Boots Alliance

- July 2020, Lucyd receives notice of allowance on 13 design patents and files two addition design patents on Lucy Lyte smartglasses.

- March 2020 LUCYD Files Patent and trademark (Vyrb™) for Voice Control App for Smartglasses

- Dec. 2018 appointed Richard Sherman American football star, as its Chief Brand Officer and brand ambassador.

- Strong IP: Lucyd has filed 24 patents and industrial designs covering its products, 13 of which have been allowed to-date.

- The online market for eyewear is US $3.8b according to Statista¹. In 2017, eight million pairs of prescription eyeglasses were sold online (4.2% of the total prescription eyeglass market)².

Tekcapital owns 100% of Lucyd Ltd.

¹ https://www.statista.com/outlook/12000000/109/eyewear/united-states#market-onlineRevenueShare
Richard Sherman, American football star and Lucyd brand ambassador sporting Lucyd Lyte E-glasses
Patented Low-sodium salt (MicroSalt®)

- Salarius aims to make a dent in cardiovascular disease by providing the best, low-sodium salt that tastes great.

- Goals: Become the leading, all natural, low-sodium salt supplier & Launch SaltMe® full flavour, low-sodium snacks in 2020.

- Dec. 2020 MicroSalt Inc. launched a U.S. crowdfund, & as of 15 Feb 2021 raised $236,874 from 485 investors at a pre-money valuation of $5m.

- Sept. 2020 Salarius forms partnership with FXM Ingredients Inc., to distribute Microsalt® throughout Mexico & LATAM.


- Salarius Ltd. confirms retail store roll out for SaltMe® snacks beginning in May 2020 and projects 100 stores will carry the brand by year’s end.

- Salarius Ltd, signs Hanks Brokerage Inc., to assist in the sale of Microsalt® to snack food companies in the southwestern United States (Jan. 2020). Sales to start in H1 2020

- Salarius signs Accurate Ingredients Inc. a food broker, to sell MicroSalt® to snack food companies (Dec. 2019).

- Salarius signs national distributor to introduce SaltMe!!® snacks into retail distribution in North America (2 March 2020). Sales to start in H1 2020

- Salarius announced it launched production and secured its first commercial client for MicroSalt® (May 2019)

- The low salt sodium ingredient market is estimated to reach US $1.76bn by 2025 according to Future Market Insights¹

¹ Sodium Reduction Ingredient Market: Global Industry Analysis and Opportunity Assessment, 2015
Salariu appointed Eduardo Souchon as a director. Eduardo has 20 years of business, brand and marketing experience focused on snacks (Brand manager for Pringles®), health products and office supplies in the consumer packaged goods and the retail industry (Proctor & Gamble).

Salariu appointed Steve McCready as a director. Steve served as Director of Product Development at Albertson’s Companies, a leading supermarket company with more than $60bn in sales and 2,300 locations.

Salariu appointed Victor H. Manzanilla as its CEO. Formerly he served as Marketing Director at Office Depot and Brand Manager at Procter & Gamble.
IP to enhance safety & efficiency of autonomous vehicles & ground-based delivery drones

- Goal: Provide IP & software solutions for autonomous vehicle manufacturers and operators to enhance their safety.

- 5 Oct. 2020 Guident announces strategic alliance with Cirrus Core Networks

- 14 Sept 2020 Guident acquires regenerative shock absorber technology. Two listed OEM's have signed NDA's for testing of the shock absorbers.

- 7 Sept 2020 Guident announces strategic alliance with Bestmile SA.

- 16 June 2020 Guident awarded patent #10,699,580 “Methods and Systems for Emergency Handoff of an Autonomous Vehicle” and has filed an additional patent entitled, “Intelligent Remote Monitoring and Control of AV’s”.

- 22 May 2020, Guident has wins Florida Atlantic University competition as one of the most promising startups in S. Florida out of a field of 200 companies.

- Acquisition of exclusive license to U.S. Patent #9,429,943 from FMAU that enables the development of software apps for controlling AV’s.

- 29 April 2019 Guident filed a new patent application for controlling autonomous vehicles after an accident.

- 25 June 2019 Guident exclusively licensed a patent application from Michigan State University for an AV communication and safety network. The patent enables AV’s to “see” not only through its sensors but also information from the sensors of nearby AV’s.

- 27 June 2019, Guident exclusively licensed patent # 9,964,948 from FIU which enables remote control of an AV by a human operator.

- According to Statista, the market for fully autonomous vehicles is projected to reach US $6 billion by 2025¹.

Guident appointed Harald Braun as its CEO & Chairman. Mr. Braun has served as CEO of Siemens Networks USA (NYSE: SI) and Aviat Networks (NASDAQ: AVNW). He served also as a Senior Executive at Nokia Siemens Networks, North America.

Guident appointed Johan De Nysschen as a director. Johanis serves as COO of Volkswagen USA and previously served as Executive Vice President of General Motors and President of the Cadillac Motor Division, President of Infiniti Motor Company Ltd., President of Audi of America Inc., and President of Audi Japan.

Guident appointed Daniel Grossman as a director and chief revenue officer. Previously, Dan helped create General Motors mobility division, “Maven”, and led all operations as COO, and was a Vice President at Zipcar, where he helped pioneer the brand globally. Avis Budget Group acquired Zipcar for ~ $500 million.

Successful and Experienced Team
Clifford Gross, Ph.D., Chairman
Cliff is passionate about commercialisation of university discoveries to improve the quality of life. He founded three companies (Biomechanics Corp., UTEK & Tekcapital) which subsequently listed, where he served as CEO and Chairman and co-founded numerous private companies including HumanCAD, Salarium, Belluscura, Lucyd and Guident. Previously he was President and CEO of Innovacorp, the provincial venture capital fund of Nova Scotia. Cliff was Acting Director of the graduate program in Biomechanics and Ergonomics at New York University, Chairman of the Nelson Rockefeller Department of Biomechanics at the New York Institute of Technology and Research Professor at the University of South Florida. He has authored several books including Too Good to Fail: Creating Marketplace Value from the World's Brightest Minds and is a named inventor on more than 30 issued patents. A number of the ergonomic products he has developed became significant commercial successes including the De Walt Cordless Drill for Black & Decker, The Parachute Chair for Knoll, the ergonomic mouse for Logitech, HumanCAD, the first PC based human CAD software and the flexible back belt, which is used to reduce back stress for individuals worldwide. Several of his products were included in a Smithsonian exhibit on ergonomic design. Cliff is a Fellow of the National Academy of Inventors and serves on the board of the State University of New York at Empire State College. He received his Ph.D. from New York University and an MBA from Oxford University.

Robert Miller, MD, Non-executive Director
Robert served a Vice Chair of the national Mayo Clinic Cancer Center Practice Committee, overseeing cancer care delivery at all of Mayo’s national sites, and Medical Director Particle Therapy at Mayo Clinic Florida. He previously served as Vice Chairman of the Board of Trustees of the Mayo Clinic Health System – Albert Lea and Austin. Professor Robert Miller is a physician-executive at the Mayo Clinic, where he has been employed for the last 25 years. He is the author of over 170 peer-reviewed papers. Robert began his scientific career as a medical physiologist at the University of Kentucky, before going on to graduate from medical school at the University of Kentucky. Robert also received an MBA from Oxford University. Robert is the Medical Director of the Maryland Proton Treatment Center and Professor at the University of Maryland.

The RT Hon Lord David Willetts FRS, Non-executive Director
The Rt Hon Lord Willetts FRS is President of the Resolution Foundation and former Minister for Universities and Science. He served as the Member of Parliament for Havant (1992-2015), and previously worked at HM Treasury and the No. 10 Policy Unit. Lord Willetts is a visiting Professor at King’s College London, Governor of the Ditchley Foundation, former Chair of the British Science Association and a member of the Council of the Institute for Fiscal Studies. He is also an Honorary Fellow of Nuffield College, Oxford. Lord Willetts has written widely on economic and social policy. His book 'The Pinch', which focused on intergenerational equity, was published in 2010, and he recently published ‘A University Education’. Lord Willetts is a graduate of Oxford university and has been awarded numerous honorary doctorates.

Louis Castro, Non-executive Director
Louis Castro has over 30 years’ experience in investment banking and broking both in the UK and overseas. Most recently he was the Chief Financial Officer at Eland Oil & Gas, a mid-cap quoted company. Previously he was Chief Executive of Northland Capital Partners in London and before this was Head of Corporate Finance at Matrix Corporate Capital and at Insigner de Beaufort. He started his career by qualifying as a Chartered Accountant with Coopers & Lybrand (now PWC). Louis chairs the Audit Committee and is a member of the Remuneration Committee. He is a Fellow of the Institute of Chartered Accountants In England and Wales and has a Double Degree in Engineering Production & Economics from Birmingham University.
Tekcapital commercialises university intellectual property for its own portfolio and as a service for university clients.

2. Built a high-value portfolio consisting of four companies: Belluscura, Lucyd, Salarius, & Guident, with exciting near-term potential growth.

3. Clients consist of 250 leading universities and companies.

4. Multi-year track record of delivering significant growth of net assets and returns on invested capital.
WHAT OUR CLIENTS SAY ABOUT US

“Tekcapital helps companies of all sizes find and acquire university discoveries to create market value. We have found their offering to be well received by our listed companies that have tried their service.”

Paul Dorfman
Managing Director
NYSE EURONEXT

“What you all do is disruptively high quality at a value no one else has been able to touch.”

Jeff Amerine
Adjunct Professor
University of Arkansas

“The analysis of the IP has been very useful and has provided a clear vision of the technologies.”

Daniela Fuentes
Directora
Dirección de Innovación y Transferencia Tecnológica
Vicerrectoría de Investigación, Santiago, Chile

“We could not be more pleased with their performance and value to our organization.”

Scott Gibson
Vice-Dean
Duke University School of Medicine
WHAT OUR CLIENTS SAY ABOUT US

“We have had a great experience with the results of the studies we have requested.”

Patricia Anguita,
SubGerente de Comercializacion de Proyectos
de Innovacion en Fundacion COPEC-UC

“We would recommend Invention Evaluator reports to any organization looking to commercialize technologies.”

Lisa Lorenzen, Executive Director
ISU Research Foundation

“IE has been an excellent tool to be able to check the strength and market potential of the technologies that we manage as a technology transfer company and investment fund in México. IE is professional, quick and affordable.”

Eduardo Valtierra, CEO

“The Invention Evaluator tool has helped us to make decisions with a greater degree of certainty of the path that the technology should follow.”

Jorge Darlas
Ejecutivo de Transferencia de Tecnología y Licenciamiento
Concepción, Chile
WHAT THE PRESS SAYS ABOUT US

“In addition to a growing portfolio of university IP investments, Tekcapital helps research institutions and businesses develop disruptive technologies and expand their portfolios of intellectual capital through leveraging their suite of powerful and convenient technology transfer services.”
- Julian Mitchell¹

Forbes

“Tekcapital released an app earlier this year that allows users to search for IP from their smartphones. This is a good way to get a feel for what is out there, identify technologies you may want, and get your creative wheels spinning.”
- Drew Hendricks²

Inc.

“An entrepreneur that wants to benefit from UIP [university intellectual property] would traditionally have to network with individual universities, making relationships with their technology transfer offices. But today entrepreneurs and international organizations facilitate a near frictionless system of access to that wealth of information.”
- Nick Hastreiter³

HUFFPOST

“Innovation is driving companies to look outside their internal R&D teams,” said Gross, who is the founder and CEO of Tekcapital, a University IP company... Capturing innovation from the crowd is now streamlined enough to become a part of any company’s survival kit.
- Andrew Medal

Entrepreneur⁴

1-https://www.forbes.com/sites/julianmitchell/2017/08/22/this-ceo-has-built-the-largest-university-research-network-for-ip-investments/#7febe9593392
3-https://www.huffpost.com/entry/the-future-of-corporate-innovation-3-ways-the-fortune_b_593d966de4b014ae8c69e193
4-https://www.entrepreneur.com/article/304483#
<table>
<thead>
<tr>
<th>Advisors</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NOMAD &amp; BROKER</strong></td>
</tr>
<tr>
<td>SP Angel Corporate Finance LLP</td>
</tr>
<tr>
<td>Prince Frederick House 35-39 Maddox Street</td>
</tr>
<tr>
<td>LONDON, W1S 2PP</td>
</tr>
<tr>
<td>+44 20 3470 0470</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SOLICITORS</th>
<th>INVESTOR RELATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bird &amp; Bird LLP</td>
<td>Flagstaff Strategic and Investor Communications</td>
</tr>
<tr>
<td>12 New Fetter Lane</td>
<td>1 King Street, LONDON, EC2V 8AU</td>
</tr>
<tr>
<td>LONDON EC4A 1JP</td>
<td>+44 (0)207 129 1474</td>
</tr>
</tbody>
</table>